We’re excited to share that the collaborative project, “International Evaluation of Modifiable Social Determinants of Health on COVID-related Mental Health Outcomes” has been approved for funding from the National Institute of Mental Health (Mental Health Research Grant, award number 1RF1MH134638-01).
Led by Dr. Jordan Smoller (Harvard University, Massachusetts General Hospital), Dr. Sarah Bauermeister (University of Oxford), and Dr. André Russowsky Brunoni (University of Sao Paulo), the COVID Global Mental Health Consortium (CGMHC) will produce a global evaluation of pandemic-related mental health outcomes using individual-level harmonized longitudinal data.
The CGHMC is comprised of 23 global cohorts representing 2.8 million participants.1 This work will address critical knowledge gaps related to the impact of policy, psychological and social factors on mental health in the COVID-19 pandemic. 2 We look forward to participating in the CGHMC and contributing to this important research.
1 CGMHC cohorts include CanPath, Health and Retirement Study, Brains for Dementia Research, English Longitudinal Study of Ageing, National Study of Health and Development, Oxwell, Generation Scotland, UK Biobank, Igana Mayuge Health and Demographic Surveillance Site, Adolescent Brain Cognitive Development Study, All of Us, Einstein Study, Mass Gen Brigham Biobank, Study to Assess Risk and Resilience in Service Members Longitudinal Study, COVID-19 Mental Health Survey, FinnGen, Taiwan Biobank, University of College London COVID Study, The Irish Longitudinal Study on Ageing, COVIDMENT, Qatar Biobank, Brazilian High Risk Cohort Study, and the Brazilian Longitudinal Study of Adult Health (ELSA).
2 CanPath was represented on this application by Dr. Ellen Sweeney, Dr. Philip Awadalla, Dr. Robin Urquhart, and Mr. Yunsong Cui. Atlantic PATH is pleased to lead this work on behalf of CanPath.
1 thought on “COVID Global Mental Health Consortium Funded – 23 cohorts with 2.8 million participants”
Comments are closed.